Insider · CIK 0002005618
Thomas DiRaimondo
officer
Files at JANX (Janux Therapeutics, Inc.). First filing Jan 2, 2026, latest Jan 2, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $34k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JANX: Janux Therapeutics, Inc.
JANXOct 9, 2026 · close 18.39
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Janux Therapeutics, Inc. | $34k 2,505 shares | -2% | 0% from low-76% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -2,505 | $13.73 | $34k | 124,425 | Jan 2, 2026 |
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +31,400 | $0.00 | $0 | 155,825 | Jan 2, 2026 |
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +109,900 | $0.00 | $0 | 109,900 | Jan 2, 2026 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 129,719 | Jan 3, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +84,000 | $0.00 | $0 | 84,000 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.